October 4, 2017
Comments Off on Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells
Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
In conclusion, the combined PE biomarkers had a high sensitivity for diagnosing MPM, although the addition of chest CT findings did not improve the sensitivity of SMRP combined with the CYFRA 21-1/CEA ratio. Combination of these biomarkers helped to rule out MPM effectively among patients at high risk of suffering MPM and would be valuable especially for old frail patients who have difficulty in undergoing invasive procedures such as thoracoscopy.October 3, 2017
Comments Off on Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma
. .October 2, 2017
Biomarkers, Biphasic or Mixed, Epithelioid, Full Archive, Pleural, Pleurectomy/decortication, Sarcomatoid, Surgery, Tumor Debulking
Comments Off on Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma
Weight of evidence analysis for assessing the genotoxic potential of carbon nanotubes
Several reference materials from the Joint Research Centre have less WoE for genotoxicity. The WoE analysis demonstrates a difference in genotoxicity for CNTs, but further research is required to unravel the physico-chemical characteristics that govern the differences in genotoxic hazard.October 1, 2017
Comments Off on Weight of evidence analysis for assessing the genotoxic potential of carbon nanotubes
Diffuse peritoneal mesothelioma: A case series of 62 patients including paraoccupational exposures to chrysotile asbestos
6 years. CONCLUSIONS: DPM occurs with both occupational and paraoccupational exposures to asbestos and may be seen in paraoccupational exposures to chrysotile asbestos.September 30, 2017
Comments Off on Diffuse peritoneal mesothelioma: A case series of 62 patients including paraoccupational exposures to chrysotile asbestos
The value of delayed phase enhanced imaging in malignant pleural mesothelioma
5-5 min following IV contrast administration. Further study of delayed phase enhancement of MPM with dynamic contrast enhanced MRI is warranted.September 29, 2017
Comments Off on The value of delayed phase enhanced imaging in malignant pleural mesothelioma
What is Mesothelioma?
Learn more about this fatal cancer, including the causes, symptoms, and treatments for both pleural and peritoneal tumors of the mesothelium at our parent site MesotheliomaCenter.
Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis
CONCLUSIONS: PMM risks from non-occupational asbestos exposure are consistent with the fibre-type potency response observed in occupational settings. By relating our findings to knowledge of exposure-response relationships in occupational settings, we can better evaluate PMM risks in communities with ambient asbestos exposures from industrial or other sources.September 28, 2017
Comments Off on Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis
Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.
Our study confirmed the prognostic role of baseline FDG-PET in a large series of MPM patients treated with first-line pemetrexed-based chemotherapy. Moreover, use of ∆SUV ≥ 25% and ∆TLG ≥ 30% as cut-off values to define early metabolic response supported the role of FDG-PET in predicting disease outcome and treatment response in patients not receiving pleurodesis.September 27, 2017
Comments Off on Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.
Role of proton-coupled folate transporter in pemetrexed-resistance of mesothelioma: clinical evidence and new pharmacological tools.
CONCLUSIONS: These findings identify for the first time PCFT as a novel mesothelioma prognostic biomarker, prompting prospective trials for its validation. Moreover, preclinical data suggest that targeting PCFT -promoter methylation might eradicate pemetrexed-resistant cells characterized by low- PCFT expression.September 26, 2017
Comments Off on Role of proton-coupled folate transporter in pemetrexed-resistance of mesothelioma: clinical evidence and new pharmacological tools.
Treatment for recurrence after extrapleural pneumonectomy for malignant pleural mesothelioma: A single institution experience
Direct tumor extension may be a major mechanism of recurrence. Aggressive treatment for recurrent MPM after EPP, including locoregional control and/or systemic chemotherapy, was important for achieving long-term survival.September 25, 2017
Chemotherapy, Extrapleural Pneumonectomy (EPP), Full Archive, Peritoneal (Abdominal Mesothelioma), Survival
Comments Off on Treatment for recurrence after extrapleural pneumonectomy for malignant pleural mesothelioma: A single institution experience